Lipid Lowering Treatment and Eligibility for PCSK9 Inhibition in Post-Myocardial Infarction Patients in Italy: Insights from Two Contemporary Nationwide Registries

INTRODUCTION: The current use of lipid lowering therapies and the eligibility for proprotein convertase subtilisin/kexin-9 (PCSK9) inhibitors of patients surviving a myocardial infarction (MI) is poorly known. METHODS: Using the data from two contemporary, nationwide, prospective, real-world registr...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cardiovasc Ther
Principais autores: Colivicchi, Furio, Massimo Gulizia, Michele, Arca, Marcello, Luigi Temporelli, Pier, Gonzini, Lucio, Venturelli, Vanessa, Morici, Nuccia, Indolfi, Ciro, Gabrielli, Domenico, De Luca, Leonardo
Formato: Artigo
Idioma:Inglês
Publicado em: Hindawi 2020
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6961602/
https://ncbi.nlm.nih.gov/pubmed/31969932
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2020/3856242
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados